Cambridge Healthtech Institute’s 2nd Annual

Multispecifics Engineering & Design

January 19-20, 2027

Cambridge Healthtech Institute’s 2nd Annual Multispecifics Engineering & Design conference focuses on the practical decisions shaping next-generation multispecific discovery, from early design strategy through functional candidate selection. The program will examine format-to-mechanism decisions across 1+1, 2+1, trispecific, and tetraspecific architectures, supported by computational and AI/ML-enabled tools for functional prediction, synergy assessment, structure optimization, and binder design. Sessions will also explore alternative building blocks, including VHHs, nanobodies, mini-proteins, affibodies, and de novo binders, as well as checkpoint and immunomodulatory bispecifics such as PD-1/VEGF and immune checkpoint-cytokine strategies. The program will also address tumor-selective engineering, including bispecific ADCs, conditional activation and masking, and logic-gated bispecifics designed to improve selectivity, internalization, and therapeutic precision.

Coverage will include, but is not limited to:

AI, COMPUTATIONAL DESIGN, AND FORMAT SELECTION

AI/ML models for:
- functional activity and anticipating synergy
- affinity/structure
Binder design for challenging targets
Format to mechanism matching:
- 1+1, 2+1, trispecific, tetraspecific—how do you decide?

ALTERNATIVE BUILDING BLOCKS

VHH/nanobody building blocks: humanized vs. naturally derived
Mini-proteins, affibodies, and de novo binders as compact multispecific components (bi-, tri-, and tetraspecific)
Format considerations

CHECKPOINT AND IMMUNOMODULATORY BISPECIFICS

PD-1/VEGF and PD-L1/VEGF bispecific mechanisms
Translating in vitro activity into in vivo immune modulation and tumor control
Next-generation checkpoint combinations beyond PD-1/VEGF
- Immune checkpoints + cytokines
  - 2, 15, 7 & 12
Deciding when checkpoint biology is better addressed through a multispecific versus combination therapy

ENGINEERING FOR TUMOR SELECTIVITY: LOGIC-GATED AND PAYLOAD-DIRECTED MULTISPECIFICS

Bispecific ADCs: improving tumor selectivity and internalization
Conditional activation and masking approaches
Logic-gated T cell engagers (AND/NOT gates) for tumor-selective activity

The deadline for priority consideration is June 26, 2026.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: